89Zr-trastuzumab and 89Zr-bevacizumab PET to Evaluate the Effect of the HSP90 Inhibitor NVP-AUY922 in Metastatic Breast Cancer Patients

2014115 citationsJournal Article

Authors

Sietske B.M. Gaykema

Carolien P. Schröder

Joanna Vitfell-Rasmussen · Institute of Cancer Research

Sue Chua · Royal Marsden Hospital

Thijs H. Oude Munnink

Adrienne H. Brouwers · ABT Molecular Imaging (United States)

Alfons H.H. Bongaerts

Mikhail Akimov · Novartis (Switzerland)

Cristina Fernandez‐Ibarra

Abstract

NVP-AUY922 showed proof-of-concept clinical response in HER2-amplified metastatic breast cancer. Early change on (89)Zr-trastuzumab PET was positively associated with change in size of individual lesions assessed by CT.

Topics & Keywords

Heat shock proteins research Radiopharmaceutical Chemistry and Applications Medical Imaging Techniques and Applications

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Cancer Research

Volume 20, Issue 15, pp. 3945-3954

DOI: 10.1158/1078-0432.ccr-14-0491

Field-Weighted Citation Impact: 6.25